A Phase II study investigating epcoritamab in the treatment of Waldenström’s macroglobulinemia
Gottfried von Keudell, MD, Beth Israel Deaconess Medical Center, Boston, MA, discusses a Phase II study investigating the safety and efficacy of epcoritamab in the treatment of Waldenström’s macroglobulinemia (WM). The trial is about to initiate with the ultimate goal of curing the disease. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.